Search tips
Search criteria 


Logo of thoraxThoraxVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
Thorax. 1998 September; 53(9): 744–752.
PMCID: PMC1745306

Asthma control during long term treatment with regular inhaled salbutamol and salmeterol


BACKGROUND—The adverse effects of long term treatment of asthma with the short acting β agonist fenoterol have been established in both epidemiological and clinical studies. A study was undertaken to investigate the efficacy and safety of long term treatment with salbutamol and salmeterol in patients with mild to moderate bronchial asthma.
METHODS—In a two centre double dummy crossover study 165 patients were randomly assigned to receive salbutamol 400 µg qid, salmeterol 50 µg bid, or placebo via a Diskhaler. All patients used salbutamol as required for symptom relief. The study comprised a four week run in and three treatment periods of 24 weeks, each of which was followed by a four week washout. Asthma control was assessed by measuring mean morning and evening peak expiratory flow rate (PEFR), a composite daily asthma score, and minor and major exacerbation rates. Washout assessments included methacholine challenge and bronchodilator dose response tests. Analysis was by intention to treat.
RESULTS—Data from 157 patients were analysed. Relative to placebo, the mean morning PEFR increased by 30 l/min (95% CI 26 to 35) for salmeterol but did not change for salbutamol. Evening PEFR increased by 25 l/min (95% CI 21 to 30) and 21 l/min (95% CI 17 to 26), respectively (p<0.001). Salmeterol improved the asthma score compared to placebo (p<0.001), but there was no overall difference with salbutamol. Only daytime symptoms were improved with salbutamol. The minor exacerbation rates were 0.29, 0.88, and 0.97 exacerbations/patient/year for salmeterol, salbutamol and placebo, respectively (p<0.0001 for salmeterol). The corresponding major exacerbation rates were 0.22, 0.51 and 0.40, respectively (p<0.03 for salmeterol). For salbutamol the asthma score deteriorated over time (p<0.01), and the time spent in major exacerbation was significantly longer compared with placebo (12.3 days (95% CI 4.2 to 20.4)) versus 8.4 days (95% CI 5.2 to 11.6), p = 0.02). There was no evidence of rebound deterioration in asthma control, lung function, or bronchial hyperresponsiveness following cessation of either active treatment, and no evidence of tolerance to salbutamol or salmeterol.
CONCLUSIONS—Regular treatment with salmeterol is effective in controlling asthma symptoms and reduces minor more than major exacerbation rates. Salbutamol was associated with improved daytime symptoms but subtle deterioration in asthma control occurred over time. Salbutamol should therefore be used only as required.

Full Text

The Full Text of this article is available as a PDF (182K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Grainger J, Woodman K, Pearce N, Crane J, Burgess C, Keane A, Beasley R. Prescribed fenoterol and death from asthma in New Zealand, 1981-7: a further case-control study. Thorax. 1991 Feb;46(2):105–111. [PMC free article] [PubMed]
  • Sears MR, Taylor DR, Print CG, Lake DC, Li QQ, Flannery EM, Yates DM, Lucas MK, Herbison GP. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet. 1990 Dec 8;336(8728):1391–1396. [PubMed]
  • Taylor DR, Sears MR, Herbison GP, Flannery EM, Print CG, Lake DC, Yates DM, Lucas MK, Li Q. Regular inhaled beta agonist in asthma: effects on exacerbations and lung function. Thorax. 1993 Feb;48(2):134–138. [PMC free article] [PubMed]
  • Taylor DR, Sears MR. Regular beta-adrenergic agonists. Evidence, not reassurance, is what is needed. Chest. 1994 Aug;106(2):552–559. [PubMed]
  • Taylor DR, Sears MR, Cockcroft DW. The beta-agonist controversy. Med Clin North Am. 1996 Jul;80(4):719–748. [PubMed]
  • Vathenen AS, Knox AJ, Higgins BG, Britton JR, Tattersfield AE. Rebound increase in bronchial responsiveness after treatment with inhaled terbutaline. Lancet. 1988 Mar 12;1(8585):554–558. [PubMed]
  • Tattersfield AE. Clinical pharmacology of long-acting beta-receptor agonists. Life Sci. 1993;52(26):2161–2169. [PubMed]
  • Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med. 1996 May;153(5):1481–1488. [PubMed]
  • Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet. 1994 Jul 23;344(8917):219–224. [PubMed]
  • Wilding P, Clark M, Thompson Coon J, Lewis S, Rushton L, Bennett J, Oborne J, Cooper S, Tattersfield AE. Effect of long-term treatment with salmeterol on asthma control: a double blind, randomised crossover study. BMJ. 1997 May 17;314(7092):1441–1446. [PMC free article] [PubMed]
  • Bone RC. A word of caution regarding a new long-acting bronchodilator. JAMA. 1994 May 11;271(18):1447–1448. [PubMed]
  • Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ. 1993 Apr 17;306(6884):1034–1037. [PMC free article] [PubMed]
  • Mann RD, Kubota K, Pearce G, Wilton L. Salmeterol: a study by prescription-event monitoring in a UK cohort of 15,407 patients. J Clin Epidemiol. 1996 Feb;49(2):247–250. [PubMed]
  • Pearlman DS, Chervinsky P, LaForce C, Seltzer JM, Southern DL, Kemp JP, Dockhorn RJ, Grossman J, Liddle RF, Yancey SW, et al. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N Engl J Med. 1992 Nov 12;327(20):1420–1425. [PubMed]
  • D'Alonzo GE, Nathan RA, Henochowicz S, Morris RJ, Ratner P, Rennard SI. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma. JAMA. 1994 May 11;271(18):1412–1416. [PubMed]
  • Grove A, Lipworth BJ. Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. Lancet. 1995 Jul 22;346(8969):201–206. [PubMed]
  • Cheung D, Timmers MC, Zwinderman AH, Bel EH, Dijkman JH, Sterk PJ. Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med. 1992 Oct 22;327(17):1198–1203. [PubMed]
  • Town GI, Hodges ID, Wilkie AT, Toop LJ, Graham P, Drennan CJ. A community-wide promotion of asthma self-management in New Zealand. Patient Educ Couns. 1995 Sep;26(1-3):219–224. [PubMed]
  • Higgins BG, Britton JR, Chinn S, Jones TD, Jenkinson D, Burney PG, Tattersfield AE. The distribution of peak expiratory flow variability in a population sample. Am Rev Respir Dis. 1989 Nov;140(5):1368–1372. [PubMed]
  • Koch GG. The use of non-parametric methods in the statistical analysis of the two-period change-over design. Biometrics. 1972 Jun;28(2):577–584. [PubMed]
  • Woolson RF, O'Gorman TW. A comparison of several tests for censored paired data. Stat Med. 1992 Jan 30;11(2):193–208. [PubMed]
  • Boulet LP, Laviolette M, Boucher S, Knight A, Hébert J, Chapman KR. A twelve-week comparison of salmeterol and salbutamol in the treatment of mild-to-moderate asthma: a Canadian multicenter study. J Allergy Clin Immunol. 1997 Jan;99(1 Pt 1):13–21. [PubMed]
  • Pauwels RA, Löfdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, Ullman A. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med. 1997 Nov 13;337(20):1405–1411. [PubMed]
  • Drazen JM, Israel E, Boushey HA, Chinchilli VM, Fahy JV, Fish JE, Lazarus SC, Lemanske RF, Martin RJ, Peters SP, et al. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network. N Engl J Med. 1996 Sep 19;335(12):841–847. [PubMed]
  • Chapman KR, Kesten S, Szalai JP. Regular vs as-needed inhaled salbutamol in asthma control. Lancet. 1994 Jun 4;343(8910):1379–1382. [PubMed]
  • Suissa S, Blais L, Ernst P. Patterns of increasing beta-agonist use and the risk of fatal or near-fatal asthma. Eur Respir J. 1994 Sep;7(9):1602–1609. [PubMed]
  • Booth H, Fishwick K, Harkawat R, Devereux G, Hendrick DJ, Walters EH. Changes in methacholine induced bronchoconstriction with the long acting beta 2 agonist salmeterol in mild to moderate asthmatic patients. Thorax. 1993 Nov;48(11):1121–1124. [PMC free article] [PubMed]
  • Cockcroft DW, Swystun VA. Functional antagonism: tolerance produced by inhaled beta 2 agonists. Thorax. 1996 Oct;51(10):1051–1056. [PMC free article] [PubMed]
  • Dickey BF, Clark RC, Barber R. Partial beta 2-agonists and their impartial assessment. Chest. 1996 Nov;110(5):1131–1132. [PubMed]

Articles from Thorax are provided here courtesy of BMJ Publishing Group